Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797438 | 0.91 | VNN1 (0.45) | HCAR3HDAC1HCAR2TP53GAA | |
| SCHEMBL14801946 | 0.90 | CA1 (0.47) | HDAC1PPARGMEN1GAAKMT2A | |
| SCHEMBL14802065 | 0.84 | PTGS2 (0.45) | HCAR3HCAR2KMT2AVNN1 | |
| SCHEMBL16012065 | 0.81 | VNN1 (0.44) | HDAC1MEN1GAAKMT2AVNN1 | |
| SCHEMBL14801811 | 0.81 | L3MBTL1 (0.45) | HCAR3HCAR2GCKVNN1 | |
| SCHEMBL16012001 | 0.79 | JAK2 (0.45) | TP53MEN1KMT2AVNN1 | |
| SCHEMBL14802056 | 0.78 | MEN1 (0.52) | HCAR3HCAR2TP53PPARGMEN1 | |
| SCHEMBL17797436 | 0.76 | VNN1 (0.44) | HCAR3HDAC1HCAR2GAAVNN1 | |
| SCHEMBL14801448 | 0.75 | CA1 (0.49) | HDAC1TP53 | |
| SCHEMBL14802054 | 0.75 | HCAR3 (0.46) | HCAR3HCAR2TP53GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422311-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150274753-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-8629150-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130078214-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274753-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, SLC10A1, HCCS | HCAR3 3484/4885HDAC1 2406/4885HCAR2 3681/4885 |
| US-20130078214-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | HCAR3 3484/4885HDAC1 2406/4885HCAR2 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.